Earnings season brings clarity—and volatility. Today's focus shifts to the pharmaceutical and payment technology sectors, where recent announcements are driving investor sentiment. InMed Pharmaceuticals (INM) is making strides in its Alzheimer's and age-related macular degeneration programs, while Medicus Pharma (MEDP) is reporting positive Phase 2 data. Separately, Nayax has released full-year results and provided forward-looking guidance.
InMed Pharmaceuticals (INM) is advancing its Alzheimer's program, with lead drug candidate INM-901, and its age-related macular degeneration program, with INM-405. The company is moving towards IND-enabling activities, targeting the initiation of Phase 1 clinical trials for Alzheimer's disease in 2027. The news seems to be well-received, as INM shares are up +4.53% today. Medicus Pharma (MEDP) is also in focus after reporting 73% clinical clearance in the 200-µg cohort of its Phase 2 SkinJect™ study at Day 57. MEDP shares show a modest gain of +0.26% following the news.
Outside of pharmaceuticals, Nayax reported full-year revenue of $400.4 million and recurring revenue growth of 29%. Net income reached $35.5 million with an Adjusted EBITDA of $61.1 million. The company is optimistic about 2026, providing revenue guidance of $510 million to $520 million. While Nayax's ticker is not directly tracked in this update, the positive guidance suggests continued growth in the payment technology sector.
SBET (Sharplink) is anticipated to release its Q4 earnings report, with expectations yet to be seen. GBTG's Q3 results showed an EPS Actual of -$0.13 compared to an EPS Estimate of 0.08, while the Revenue Actual was $674.00M compared to a Revenue Estimate of 615.37M, showing a mixed performance. Expectations are set. Now comes execution.